FDA staff finds Intercept's liver drug effective as monotherapy
The U.S. Food and Drug Administration's staff reviewers on Tuesday supported the use of Intercept Pharmaceuticals Inc's liver drug as a monotherapy in patients who did not respond to standard-of-care treatment.
No comments:
Post a Comment